Financials
Financial year 2025
BAUSCH & LOMB PHARMA from Wavre, company number BE0439621618, closed financial year 2025 with a result of € 871,860 after tax. For that financial year BAUSCH & LOMB PHARMA recorded revenue of € 37.4 million and equity of € 751,241. Compared with financial year 2024, the result moved from € 1 million to € 871,860. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 751,241
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 871,860
▼ 13% vs 2024
Profit after tax over the fiscal year.
€ 996,878
▲ 31% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 871,860 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
11.6
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.4 million
▼ 6% vs 2024
€ 123,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 7 million
▲ 26% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 74 days on average.
€ 477,314
▼ 24% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 29,426,532 | € 30,394,109 | € 35,712,415 | € 37,404,611 | ▲ 5% |
| Profit after taxes | € 449,627 | € 693,191 | € 1,002,946 | € 871,860 | ▼ 13% |
| Equity | € 751,241 | € 751,241 | € 751,241 | € 751,241 | |
| Total debts | € 7,171,210 | € 13,920,358 | € 7,323,300 | € 8,347,142 | ▲ 14% |
| Cash | € 1,249,719 | € 691,206 | € 761,147 | € 996,878 | ▲ 31% |
| Retained profit | € 68,295 | € 68,295 | € 68,295 | € 68,295 | |
| Dividend | € 449,627 | € 693,191 | € 1,002,946 | € 871,860 | ▼ 13% |
| Bank debt | € 0 | € 1,512,367 | € 125,327 | € 0 | ▼ 100% |
| Balance sheet total | € 8,067,109 | € 14,809,050 | € 8,074,541 | € 9,168,584 | ▲ 14% |
| Employees (FTE) | 11.8 | 12.1 | 11.3 | 11.6 | ▲ 0.3 |
Key figures of BAUSCH & LOMB PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BAUSCH & LOMB PHARMA?
What happened at BAUSCH & LOMB PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Eberhard KUEHNE stepped down as director. NBB
- Manoj Kumar PANDA stepped down as director. NBB
- Pierre GUIBOURG stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 871,860 (▼ 13% vs 2024). Source: NBB ↗
- Eberhard KUEHNE became a director. NBB
- Manoj Kumar PANDA became a director. NBB
- New establishment in Aalst. KBO
- Pierre GUIBOURG became a director. NBB
In short
From € 449,627 profit in 2022 to € 871,860 profit in 2025.
Paid € 1.2 million in corporate taxes since 2022.
Best year ever: 2024, with € 1 million profit.
Paid out € 3 million in dividends to the owners in total.
A new publication or filing at BAUSCH & LOMB PHARMA? We notify you, reason included.
Follow BAUSCH & LOMB PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Manoj Kumar PANDA
Director
since 2022 · until 2028
Pierre GUIBOURG
Director
since 2022 · until 2028
Eberhard KUEHNE
Director
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Place Alphonse Bosch 19 box 2
1300 Wavre
Korte Keppestraat 19
9320 Aalst
Active since 1 September 2022
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0439.621.618
- VAT number
- BE 0439.621.618
- Registered office
- Place Alphonse Bosch 19 bus 2, 1300 Wavre
- Names & denominations
- BAUSCH & LOMB PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 December 1989
- Peppol
- Active · Active since 22 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten